Departments of Immunology and Rheumatology, Hôpital Edouard Herriot and 1 Department of Hepatology, Hôtel Dieu, Lyon, France.
Correspondence to: P. Miossec, Clinical Immunology Unit, Departments of Immunology and Rheumatology, Hôpital Edouard Herriot, 69437 Lyon Cedex 03, France. E-mail: miossec{at}univ-lyon1.fr
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Methods. We performed a retrospective study of clinical, radiological and biological data on 21 rheumatology patients (Group I) presenting symptoms consistent with a chronic inflammatory arthritis with a known HCV infection and compared them with 41 members of an HCV support association (Group II).
Results. Symptoms of myalgia, sicca syndrome, Raynaud's phenomenon or paraesthesias were similarly frequent in the two groups. However, inflammatory joint pain and joint swelling were more common in Group I. In this group rheumatoid factor was positive in 48%, antinuclear antibodies in 26%, cryoglobulin in 44% and a reduced complement level in 63%. The majority of patients from Group I treated with methotrexate demonstrated an amelioration of the rheumatological symptoms with few negative outcomes. Regarding interferon-alpha therapy and rheumatological symptomsin Groups I and II respectively 50 and 66% demonstrated a deterioration, 33 and 30% showed no change and 17 and 4% showed an amelioration.
Conclusion. Rheumatological symptoms are common in patients chronically infected with HCV. It is essential to individualize the role of treatment with interferon-alpha and to consider the use of methotrexate for difficult cases.
KEY WORDS: Arthritis, Hepatitis C, Methotrexate, Interferon
![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
In addition to its hepatic effects, chronic infection with the HCV is responsible for numerous extrahepatic manifestations [2, 3], of which the rheumatological manifestations are amongst the most frequent. Recently, there has been a surge of interest in the relationship between chronic HCV infection and systemic autoimmune diseases such as Sjögren's syndrome (SS), rheumatoid arthritis (RA), polyarteritis nodosa, systemic lupus erythematosus and the antiphospholipid syndrome. However, the bulk of the data are based on small sample groups and case studies, while in the larger multicentre trials of HCV treatment, patients with autoimmune or extrahepatic features were excluded [4].
In this context, the management of severe rheumatological manifestations or a coexisting inflammatory arthritis is difficult. The clinical use of drugs such as methotrexate in this context has only been on a case-by-case basis, due to their well-known hepatic complications. Consequently, there is a paucity of studies demonstrating the hepatic toxicity as well as the actual efficacy of methotrexate.
The goal of this study was to investigate an HCV positive population followed in a rheumatology department for a chronic inflammatory arthritis, and to compare it with a similar population of HCV-positive patients not known to a rheumatology department. Our aims were to clarify the different types of inflammatory arthritis amongst random patients infected with HCV, to look for factors predisposing to the development of rheumatological symptoms and to document the beneficial and deleterious effects of methotrexate and interferon therapy with regards to the rheumatological manifestations.
![]() |
Patients and methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Both groups were studied with the same specifically designed questionnaire, with the answers recorded anonymously. Details are given in the supplementary data available at Rheumatology Online. The questionnaire, distributed to Group I patients during their hospital examination and to Group II patients by mail, collected information on patient demographics, the history of the hepatitis and treatments received, the rheumatological manifestations (arthralgia, arthritis, myalgia, SS, peripheral neuropathy) and the effects of treatments on these manifestations. The questions were precise enough to distinguish between inflammatory and mechanical joint disease. In addition, patients from Group I on methotrexate were submitted to the same questions on the efficacy and tolerance of the drug. Biological and liver biopsy details were not available for Group II patients because of the anonymous nature of the survey.
Immunological parameters such as rheumatoid factor (RF), antinuclear antibodies (ANA) (specifically anti-SSA/SSB), cryoglobulin and complement levels were collected for nearly all patients, as well as erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) values. The viral activity of the hepatitis was assessed by the transaminase level, the viral load measured by polymerase chain reaction, and for a proportion of patients a liver biopsy was performed with an evaluation of the degree of histological activity and fibrosis with the Metavir score [5], which measures the activity score (A) from 03 and the fibrosis score (F) from 04.
Statistical analysis
Statistical analysis of the qualitative data was performed with the use of the 2 test or the Fisher test. For the quantitative data, a Student's t-test was used. The difference was considered to be significant for a P score of <0.05.
![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|
Regarding biological manifestations, an elevation of the transaminases was observed in 14 patients (66.7%). A viraemia was present in 14 of 18 patients (77.7%), indicating that four patients, previously positive for HCV, had become negative. The mean ESR value was 18.7±8.4 mm/h (range 640) and CRP 9.2±11.1 mg/l (range 341). Rheumatoid factor was present in 10/21 (47.6%), cryoglobulin in 8/18 (44.4%) and a reduced complement level (CH50) in 12/19 (63.2%). Antinuclear antibodies were detected by immunofluorescence in 5/19 (26.3%), one positive for anti-SSA/SSB, one for anti-ribonucleoprotein (anti-RNP). In 13 patients a hepatic biopsy was performed, with an average Metavir activity score of 1.18±0.98 and a fibrosis score of 2.3±1.16. One patient had cirrhosis, two a pre-cirrhotic state and three patients widespread fibrosis.
Amongst 10 of these patients, the rheumatological manifestations had been severe enough to require treatment by disease-modifying anti-rheumatic drugs (DMARDs), the most commonly prescribed agents being methotrexate (seven cases) and corticosteroids (five cases).
Definition of the Group II patient population
The 41 patients in Group II consisted of 22 females and 19 males with a mean age of 56.1±12.6 yr (range 3478 yr) and mean duration of HCV 10.3±8.7 yr (range 345 yr), which was significantly less than Group I (P = 0.015). Thirty-two patients had received interferon-alpha therapy (78%). Twenty-seven patients (65.8%) reported articular pains. In 14/27 patients, arthralgias were inflammatory (34.1%) with frank joint swelling in five (12.2%), sicca syndrome in 18 (43.9%), myalgias in 11 (26.8%), paraesthesias of the lower limbs in nine (22.0%) and Raynaud's phenomenon in four (9.8%).
A comparison of the two patient populations is given in Table 1, with no difference for myalgia, sicca syndrome, Raynaud's phenomenon or paraesthesias. Inflammatory joint pain and joint swelling were significantly more common in Group I. However, it is critical to note the high frequency of rheumatological complaints in the HCV population not directly seen in a rheumatology unit.
Effect of methotrexate treatment on the rheumatological manifestations
Seven patients in Group I (and none in Group II) had been treated with methotrexate because of the articular manifestations (Table 2). All seven were women with a mean age of 54.8±6.8 yr and a mean duration of HCV infection of 17.4±9.3 yr. Two had a clinical picture consistent with SS (according to the AmericanEuropean Consensus Group criteria, with characteristic salivary gland biopsies), three patients had an RA-like symmetrical, inflammatory arthritis [all three patients satisfied the American College of Rheumatology (ACR) criteria of RA] and the final patient an oligoarthritis with recurrent episodes of episcleritis.
|
Effect of interferon-alpha treatment on the disease manifestations
In Group I, 13/21 patients (61.9%), 10 women and 3 men, mean age 57.5±9.3 yr, mean duration of HCV hepatitis 13.6±7.4 yr, had been treated with interferon-alpha. Eight patients had been treated with interferon-alpha and ribavirin and five with interferon-alpha monotherapy (Table 3). Between the different patients treated or not with interferon-alpha in Group I there were no significant differences with regards to the presence of antinuclear antibodies, cryoglobulin or a positive rheumatoid factor or the degree of hepatic fibrosis. Summarizing the outcomes of 12/13 patients following treatment with interferon-alpha: four (33.3%) had no clinical effect on the rheumatological manifestations, six (50%) a negative effect (three with an aggravation of symptoms and three with the development of a chronic inflammatory arthritis with therapy) and only the final two patients (16.7%) reported an amelioration.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Although there is no specific pattern to HCV-related arthritis, two subsets have been described: an RA-like symmetrical, inflammatory polyarthritis involving mainly small joints, but without destruction, and a mono- or oligo-arthritis involving medium-sized and large joints, which often displays an intermittent course and is associated with the presence of cryoglobulins [2, 3]. Anti-citrullinated peptide antibodies (CCP) are absent in these patients, but present in 60% of patients with established RA associated with HCV positive serology [6].
If we divide the rheumatology group into two subgroups, the first consisting of all the patients who had received disease-modifying treatment (and thus we can assume the more severe cases) and the second subgroup with less severe symptomatology, we found no difference regarding the state of hepatic fibrosis, the levels of ESR and CRP, rheumatoid factor, antinuclear antibodies, reduced complement levels or the presence of a cryoglobulin. In a study of 28 HCV-infected patients with arthritis, 43% had detectable cryoglobulin, which was remarkably similar to the 44% (8/18) of patients in the rheumatology group of our study [7].
One of the interesting trends from this study was the apparent dissociation between the frank inflammatory nature of the rheumatological manifestations and the relative normality of ESR and CRP, as described previously [8]. It is important that these aspects are well understood. Otherwise HCV-positive patients with vague symptoms of fatigue, arthralgia and myalgia (with the typical age/sex distribution) in the absence of a biological inflammatory syndrome could well be considered to have primary fibromyalgia, if the positive hepatitis serology is unknown.
Turning to the therapeutic aspects of our study, seven patients were treated with methotrexate without deleterious effects on hepatic function or the course of the HCV infection. In a study on 600 RA patients tested for HCV [9], the two patients who had been treated with methotrexate (both for a period of greater than 6 months) showed no modifications of the transaminase level. Long-term studies are required to indicate whether chronic administration of methotrexate leads to an increased risk of hepatic fibrosis. Methotrexate, with not only its well-described anti-inflammatory actions at the hepatic level [10, 11] but in addition its immunosuppressive properties, may play an important role in the treatment of the rheumatological symptoms of HCV [12]. The discussion regarding the treatment options of these manifestations will become even more complex with the novel agents such as the tumour necrosis factor (TNF) inhibitors. Indeed, a small recent study found no significant variations in transaminases or HCV viraemia in RA patients with HCV treated with TNF antagonists [13].
The efficacy of interferon-alpha in the treatment of chronic HCV infection is well known, in particular in association with ribavirin. Another beneficial role of interferon-alpha treatment in HCV infection relates to the treatment of the clinical manifestations of cryoglobulinaemia [14]. However, there is a paucity of literature on the efficacy of interferon-alpha on the other rheumatological manifestations associated with HCV. In a study of 21 HCV-positive patients presenting symptoms consistent with a diagnosis of RA, a beneficial therapeutic response to interferon-alpha therapy was demonstrated in 76% of cases [7]. However, as 43% of patients had detectable cryoglobulin many of these cases could equally be classified as mixed cryoglobulinaemia. On the other hand, interferon-alpha therapy has also been implicated in the development of autoimmune dysfunction [15].
Out of our 62 patients, 45 (72.5%) had received interferon-alpha and 29 responded to the question on its clinical effects. Only three (7.7%) reported an amelioration, 12 (30.8%) no change, 14 (35.9%) an aggravation and the final 10 (25.6%) the development of new inflammatory rheumatological symptoms. For the majority of these latter patients, these symptoms disappeared with the cessation of interferon-alpha therapy.
![]() |
Conclusion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
The authors have declared no conflicts of interest.
![]() |
Supplementary data |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Supplementary data are available at Rheumatology Online.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
|